Metalyse® 25 mg (TENECTEPLASE) is available for the thrombolytic treatment of acute ischaemic stroke (AIS) within 4.5 hours from last known well and after exclusion of intracranial haemorrhage¹

Because Every
Minute Matters

Metalyse 25 mg (tenecteplase) for the treatment of acute ischaemic stroke

Since Boehringer Ingelheim launched Actilyse® (alteplase) for the treatment of AIS in 2002, it has become a global standard of care in AIS.^2–7 In 2024, Metalyse 25 mg (tenecteplase) was licensed for the thrombolytic treatment of AIS,¹ offering more treatment options for patients and HCPs.

IV thrombolysis with Actilyse or Metalyse 25 mg can be initiated within 4.5 hours of known onset of AIS, as reflected in the National Clinical Guideline for Stroke for the UK and Ireland.⁵

Metalyse 25 mg is a genetically modified version of Actilyse.¹ With five weight-based dosing tiers, a single IV bolus, and no requirement for an IV infusion pump, Metalyse 25 mg is simpler and quicker to administer than Actilyse.^1,8,9

Switching to Metalyse 25 mg could save you and your patient precious minutes, while delivering non-inferior efficacy and comparable safety to Actilyse.^1,8,10–12

Explore the links below to find out more about how Metalyse 25 mg could benefit your AIS patients.

ThiNK Stroke

Two doctors in blue scrubs wheeling patient on hospital bed

ThiNK Stroke

Clinical Trial Data

Needle entering stopper of Metalyse® 25 mg (tenecteplase) vial

Clinical Trial Data

Dosing & Administration

Dosing & Administration

Contraindications

Doctor with clipboard talking to patient in hospital bed

Contraindications

Time is Brain

Doctors rushing to help patient in hospital bed

Time is Brain

^* Metalyse 25 mg may help streamline workflows due to simple administration.^9,13

Abbreviations

AIS: acute ischaemic stroke, HCP: Healthcare Professional, IV: intravenous.

References

Metalyse® 25 mg (tenecteplase) Summary of Product Characteristics.
Berge E, et al. Eur Stroke J. 2021;6(1);I–LXII.
National Institute for Health and Care Excellence (NICE). Tenecteplase for treating acute ischaemic stroke. July 2024. Available at: www.nice.org.uk/guidance/ta990/resources/tenecteplase-for-treating-acute-ischaemic-stroke-pdf-82615964148421 (Accessed July 2025).
Powers WJ, et al. Stroke. 2019;50;e344–e418.
National Clinical Guideline for Stroke for the UK and Ireland. London: Intercollegiate Stroke Working Party; 2023 May 4. Available at: https://www.strokeguideline.org. (Accessed July 2025).
Stroke Foundation. The Australia and New Zealand Living Clinical Guidelines for Stroke Management. Available at: https://files.magicapp.org/guideline/1f71df73-ade3-4154-96d7-0cb4a8b06748/published_guideline_7406-11_0.pdf. (Accessed July 2025).
Heran M, et al. Can J Neurol Sci. 2024;51(1):1–31.
Actilyse® (alteplase) Summary of Product Characteristics.
Zitek T, et al. West J Emerg Med. 2020;21:199–202.
Menon BK, et al. Lancet. 2022;400:161–169.
Campbell BCV, et al. N Engl J Med. 2018;378:1573–1582.
Muir K, et al. Lancet Neurol. 2024;23:1087–1096.
Ranta A, et al. Eur Stroke J. 2023;8:942–946.

PC-GB-110816 V3 August 2025

Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.

Because Every
Minute Matters

Metalyse 25 mg (tenecteplase) for the treatment of acute ischaemic stroke